Advertisement

Testing for Inherited Susceptibility to Breast Cancer

  • Mark Robson
    Affiliations
    Breast Medicine Service, Department of Medicine, Memorial Hospital for Treatment of Cancer and Allied Disease, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 300 East 66th Street, Room 813, New York, NY 10065, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33
        • Pharoah P.D.
        • Antoniou A.C.
        • Easton D.F.
        • et al.
        Polygenes, risk prediction, and targeted prevention of breast cancer.
        N Engl J Med. 2008; 358: 2796-2803
        • Mucci L.A.
        • Hjelmborg J.B.
        • Harris J.R.
        • et al.
        Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.
        JAMA. 2016; 315: 68-76
        • Benedict W.L.
        Homologous Retinoblastoma in Identical Twins.
        Trans Am Ophthalmol Soc. 1929; 27: 173-176
        • Li F.P.
        • Fraumeni Jr., J.F.
        Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?.
        Ann Intern Med. 1969; 71: 747-752
        • Lynch H.T.
        • Krush A.J.
        Carcinoma of the breast and ovary in three families.
        Surg Gynecol Obstet. 1971; 133: 644-648
        • Lynch H.T.
        • Krush A.J.
        • Larsen A.L.
        Heredity and multiple primary malignant neoplasms: six cancer families.
        Am J Med Sci. 1967; 254: 322-329
        • Hall J.M.
        • Lee M.K.
        • Newman B.
        • et al.
        Linkage of early-onset familial breast cancer to chromosome 17q21.
        Science. 1990; 250: 1684-1689
        • Newman B.
        • Austin M.A.
        • Lee M.
        • et al.
        Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families.
        Proc Natl Acad Sci U S A. 1988; 85: 3044-3048
        • Miki Y.
        • Swensen J.
        • Shattuck-Eidens D.
        • et al.
        A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
        Science. 1994; 266: 66-71
        • Wooster R.
        • Bignell G.
        • Lancaster J.
        • et al.
        Identification of the breast cancer susceptibility gene BRCA2.
        Nature. 1995; 378: 789-792
        • Hansford S.
        • Kaurah P.
        • Li-Chang H.
        • et al.
        Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.
        JAMA Oncol. 2015; 1: 23-32
        • Hearle N.
        • Schumacher V.
        • Menko F.H.
        • et al.
        Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.
        Clin Cancer Res. 2006; 12: 3209-3215
        • Hendricks L.A.J.
        • Hoogerbrugge N.
        • Schuurs-Hoeijmakers J.H.M.
        • et al.
        A review on age-related cancer risks in PTEN hamartoma tumor syndrome.
        Clin Genet. 2021; 99: 219-225
        • Swift M.
        • Reitnauer P.J.
        • Morrell D.
        • et al.
        Breast and other cancers in families with ataxia-telangiectasia.
        N Engl J Med. 1987; 316: 1289-1294
        • Bell D.W.
        • Varley J.M.
        • Szydlo T.E.
        • et al.
        Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
        Science. 1999; 286: 2528-2531
        • Meijers-Heijboer H.
        • van den Ouweland A.
        • Klijn J.
        • et al.
        Low-penetrance susceptibility to breast cancer due to CHEK2(∗)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
        Nat Genet. 2002; 31: 55-59
        • Collaborative Group on Hormonal Factors in Breast C.
        Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.
        Lancet. 2001; 358: 1389-1399
        • Pharoah P.D.
        • Day N.E.
        • Duffy S.
        • et al.
        Family history and the risk of breast cancer: a systematic review and meta-analysis.
        Int J Cancer. 1997; 71: 800-809
        • Breast Cancer Association C.
        • Dorling L.
        • Carvalho S.
        • et al.
        Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
        N Engl J Med. 2021; 384: 428-439
        • Hu C.
        • Hart S.N.
        • Gnanaolivu R.
        • et al.
        A Population-Based Study of Genes Previously Implicated in Breast Cancer.
        N Engl J Med. 2021; 384: 440-451
        • Genomes Project C.
        • Auton A.
        • Brooks L.D.
        • et al.
        A global reference for human genetic variation.
        Nature. 2015; 526: 68-74
        • Uffelmann E.
        • Huang Q.Q.
        • Munung N.S.
        • et al.
        Genome-wide association studies.
        Nat Rev Methods Primers. 2021; 1: 59
        • Lilyquist J.
        • Ruddy K.J.
        • Vachon C.M.
        • et al.
        Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future.
        Cancer Epidemiol Biomarkers Prev. 2018; 27: 380-394
        • Mavaddat N.
        • Michailidou K.
        • Dennis J.
        • et al.
        Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.
        Am J Hum Genet. 2019; 104: 21-34
        • Lakeman I.M.M.
        • van den Broek A.J.
        • Vos J.A.M.
        • et al.
        The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
        Genet Med. 2021; 23: 1726-1737
        • Kuchenbaecker K.B.
        • McGuffog L.
        • Barrowdale D.
        • et al.
        Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
        J Natl Cancer Inst. 2017; 109
        • Gao C.
        • Polley E.C.
        • Hart S.N.
        • et al.
        Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
        J Clin Oncol. 2021; 39: 2564-2573
        • Binkley T.K.
        • Binkley C.
        Porcelain-fused-to-metal crowns as replacements for denture teeth in removable partial denture construction.
        J Prosthet Dent. 1987; 58: 53-56
        • Barnes D.R.
        • Rookus M.A.
        • McGuffog L.
        • et al.
        Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
        Genet Med. 2020; 22: 1653-1666
        • Kapoor P.M.
        • Mavaddat N.
        • Choudhury P.P.
        • et al.
        Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.
        J Natl Cancer Inst. 2021; 113: 329-337
        • Carver T.
        • Hartley S.
        • Lee A.
        • et al.
        CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants.
        Cancer Epidemiol Biomarkers Prev. 2021; 30: 469-473
        • Gallagher S.
        • Hughes E.
        • Kurian A.W.
        • et al.
        Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model.
        JCO Precis Oncol. 2021; : 5
        • Hughes E.
        • Tshiaba P.
        • Wagner S.
        • et al.
        Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.
        JCO Precis Oncol. 2021; : 5
        • Hurson A.N.
        • Pal Choudhury P.
        • Gao C.
        • et al.
        Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.
        Int J Epidemiol. 2022; 50: 1897-1911
        • Lee A.
        • Mavaddat N.
        • Wilcox A.N.
        • et al.
        BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
        Genet Med. 2019; 21: 1708-1718
        • Polygenic Risk Score Task Force of the International Common Disease A
        Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.
        Nat Med. 2021; 27: 1876-1884
        • Easton D.F.
        • Ford D.
        • Bishop D.T.
        Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
        Am J Hum Genet. 1995; 56: 265-271
        • Easton D.F.
        • Steele L.
        • Fields P.
        • et al.
        Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.
        Am J Hum Genet. 1997; 61: 120-128
        • Stefanek M.E.
        Bilateral prophylactic mastectomy: issues and concerns.
        J Natl Cancer Inst Monogr. 1995; : 37-42
        • Struewing J.P.
        • Watson P.
        • Easton D.F.
        • et al.
        Prophylactic oophorectomy in inherited breast/ovarian cancer families.
        J Natl Cancer Inst Monogr. 1995; : 33-35
        • Burke W.
        • Kahn M.J.
        • Garber J.E.
        • et al.
        First do no harm" also applies to cancer susceptibility testing.
        Cancer J Sci Am. 1996; 2: 250-252
        • Lerman C.
        • Narod S.
        • Schulman K.
        • et al.
        BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
        JAMA. 1996; 275: 1885-1892
        • Wilfond B.S.
        • Rothenberg K.H.
        • Thomson E.J.
        • et al.
        Cancer genetic susceptibility testing: ethical and policy implications for future research and clinical practice. Cancer Genetic Studies Consortium, National Institutes of Health.
        J Law Med Ethics. 1997; 25 (230): 243-251
        • Geller G.
        • Botkin J.R.
        • Green M.J.
        • et al.
        Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent.
        JAMA. 1997; 277: 1467-1474
        • Biesecker B.B.
        • Boehnke M.
        • Calzone K.
        • et al.
        Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.
        JAMA. 1993; 269: 1970-1974
      1. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition.
        Am J Hum Genet. 1994; 55: i-iv
        • Green M.J.
        • Botkin J.R.
        Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests.
        Ann Intern Med. 2003; 138: 571-575
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • et al.
        Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
        JAMA. 2017; 317: 2402-2416
        • Schwartz M.D.
        • Peshkin B.N.
        • Hughes C.
        • et al.
        Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample.
        J Clin Oncol. 2002; 20: 514-520
        • Warner E.
        Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations.
        Ann Oncol. 2011; 22: i44-i49
        • Rebbeck T.R.
        • Lynch H.T.
        • Neuhausen S.L.
        • et al.
        Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
        N Engl J Med. 2002; 346: 1616-1622
        • Rebbeck T.R.
        • Friebel T.
        • Lynch H.T.
        • et al.
        Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
        J Clin Oncol. 2004; 22: 1055-1062
        • Passaperuma K.
        • Warner E.
        • Causer P.A.
        • et al.
        Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
        Br J Cancer. 2012; 107: 24-30
        • Meijers-Heijboer H.
        • van Geel B.
        • van Putten W.L.
        • et al.
        Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2001; 345: 159-164
        • Li X.
        • You R.
        • Wang X.
        • et al.
        Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
        Clin Cancer Res. 2016; 22: 3971-3981
        • Kauff N.D.
        • Satagopan J.M.
        • Robson M.E.
        • et al.
        Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2002; 346: 1609-1615
        • Hartmann L.C.
        • Sellers T.A.
        • Schaid D.J.
        • et al.
        Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
        J Natl Cancer Inst. 2001; 93: 1633-1637
        • Chiarelli A.M.
        • Prummel M.V.
        • Muradali D.
        • et al.
        Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
        J Clin Oncol. 2014; 32: 2224-2230
        • Force USPST
        • Owens D.K.
        • Davidson K.W.
        • et al.
        Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
        JAMA. 2019; 322: 652-665
        • Force USPST
        Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
        Ann Intern Med. 2005; 143: 355-361
        • Heemskerk-Gerritsen B.A.
        • Rookus M.A.
        • Aalfs C.M.
        • et al.
        Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
        Int J Cancer. 2015; 136: 668-677
        • Evans D.G.
        • Ingham S.L.
        • Baildam A.
        • et al.
        Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
        Breast Cancer Res Treat. 2013; 140: 135-142
        • Trombetta M.G.
        • Dragun A.
        • Mayr N.A.
        • et al.
        ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
        Pract Radiat Oncol. 2020; 10: 235-242
        • Tutt A.
        • Tovey H.
        • Cheang M.C.U.
        • et al.
        Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
        Nat Med. 2018; 24: 628-637
        • Robson M.
        • Im S.A.
        • Senkus E.
        • et al.
        Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
        N Engl J Med. 2017; 377: 523-533
        • Litton J.K.
        • Rugo H.S.
        • Ettl J.
        • et al.
        Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
        N Engl J Med. 2018; 379: 753-763
        • Gelmon K.A.
        • Fasching P.A.
        • Couch F.J.
        • et al.
        Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
        Eur J Cancer. 2021; 152: 68-77
        • Tutt A.N.J.
        • Garber J.E.
        • Kaufman B.
        • et al.
        Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
        N Engl J Med. 2021; 384: 2394-2405
        • Manahan E.R.
        • Kuerer H.M.
        • Sebastian M.
        • et al.
        Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
        Ann Surg Oncol. 2019; 26: 3025-3031
        • Yoon S.Y.
        • Wong S.W.
        • Lim J.
        • et al.
        Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.
        J Med Genet. 2022; 59: 220-229
        • Stromsvik N.
        • Olsson P.
        • Gravdehaug B.
        • et al.
        It was an important part of my treATMent": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing.
        Hered Cancer Clin Pract. 2022; 20: 6
        • Ramsey M.L.
        • Tomlinson J.
        • Pearlman R.
        • et al.
        Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
        Fam Cancer. 2022; 17: 1-7
        • Hamilton J.G.
        • Symecko H.
        • Spielman K.
        • et al.
        Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
        Genet Med. 2021; 23: 2105-2113
        • Bokkers K.
        • Zweemer R.P.
        • Koudijs M.J.
        • et al.
        Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer.
        Fam Cancer. 2022; 21: 295-304
        • Bokkers K.
        • Vlaming M.
        • Engelhardt E.G.
        • et al.
        The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review.
        Cancers (Basel). 2022; 14
        • Offit K.
        • Tkachuk K.A.
        • Stadler Z.K.
        • et al.
        Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.
        J Clin Oncol. 2020; 38: 1398-1408
        • Sun L.
        • Brentnall A.
        • Patel S.
        • et al.
        A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
        JAMA Oncol. 2019; 5: 1718-1730https://doi.org/10.1001/jamaoncol.2019.3323
        • Norum J.
        • Grindedal E.M.
        • Heramb C.
        • et al.
        BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.
        ESMO Open. 2018; 3: e000328
        • Beitsch P.D.
        • Whitworth P.W.
        • Hughes K.
        • et al.
        Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?.
        J Clin Oncol. 2019; 37: 453-460
        • Yadav S.
        • Hu C.
        • Hart S.N.
        • et al.
        Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
        J Clin Oncol. 2020; 38: 1409-1418
        • Boddicker N.J.
        • Hu C.
        • Weitzel J.N.
        • et al.
        Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
        J Clin Oncol. 2021; 39: 3430-3440
        • Desai N.V.
        • Yadav S.
        • Batalini F.
        • et al.
        Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
        Cancer. 2021; 127: 828-833
        • Tung N.M.
        • Boughey J.C.
        • Pierce L.J.
        • et al.
        Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
        J Clin Oncol. 2020; 38: 2080-2106
        • Robson M.
        Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
        J Clin Oncol. 2021; 39: 2528-2534